1800 244 735

Helpline (02) 9874 9777

Oz Buzz Updates: Day 3

Our final daily report from the Huntington’s disease World Congress brings together all the live updates from our twitter feed. Video of both Oz Buzz sessions – with news, interviews and features – is on YouTube now and will be available to watch at HDBuzz.net later this week.

Wednesday, September 14, 2011

8:33 – Jeff and Ed are now live from day 3 of the World Congress on HD!

8:40 – Jeff: HD may be much more common than we thought – Michael Hayden

8:47 – Jeff: HD is an increasing burden on the elderly, who in the past may not have lived long enough to have symptoms – Hayden

9:02 – Ed: More on increased ‘prevalence’ of HD – how it’s more common than we thought

9:07 – Ed: studies in sperm helping to predict whether a CAG repeat in the ‘gray area’ will cause problems for next generation

9:13 – We need to move away from talking about ‘onset’ in Huntington’s – symptoms begin gradually over years – Dr Mark Guttman

9:32 – Huntington’s disease causes a wide variety of symptoms so doctors should always bear it in mind when seeing patients- Elizabeth McKusker

10:36 – Ed’s reporting from the ‘Science: omics’ session – Jeff’s in ‘International models of care’.

10:37 – Ed: ‘omics’ means measuring loads of things at once. Like genomics (looking at tons of genes)

10:45 – Ed: Metabolomics is measuring metabolites – small molecules in blood. Wayne Matson’s done it in HD & finds interesting changes

10:54 – Ed: Levels of a chemical I3PA seem to be reduced in blood of HD patients and HD mice. Not yet clear why but could be useful – Matson

11:02 – Jeff: HD patient care in Australia is difficult because of complex health care administration – Andrew Churchyard

11:00 – Jeff: Significant numbers of HD families don’t interact with the medical system, and we don’t know why – Churchyard

11:11 – Ed: Brain immune cells called microglia are abnormal in HD mice – Dr Blair Leavitt – are they helping or harming?

11:13 – Ed: There are also changes in the mice’s brain blood vessels that could increase the cross-talk between brain & body – Leavitt

11:26 – Jeff: Access to medical services for HD families in South Africa is limited – Amanda Krause

11:34 – Jeff: In black Africans a disease called ‘HD like 2’ looks very much like HD, but is caused by a different mutation – Krause

11:38 – Ed: Ruth Luthi-Carter examines which genes are more and less activated in different mouse models of HD & compares them to humans

11:51 – Ed: These gene activation changes could help us to understand the disease and develop and test new drugs – Luthi-Carter

12:06 – Ed: Proteins do stuff by sticking to each other. Mutant and normal huntingtin stick to different groups of partners – Chris Ross

12:11 – Ed: An international consortium of researchers is using stem cell models to help understand Huntington’s disease

12:18 – Jeff: Francisco Cardoso – new Latin american HD network active at rlah.org

12:20 – Ed: The consortium has figured out the recipe for turning stem cells into the neurons most affected by HD. Very valuable research tool

12:27 – Red Latino-Americana de Huntington: investigación de tratamientos efectivos para la Enfermedad de Huntington

12:43 – Ed: Comparing gene switching and behavior across mouse models shows that different models mimic different aspects of HD Lesley Jones

12:44 – Ed: One of the mouse models called Q150 actually produces less huntingtin protein overall – weird but important to know about – Jones

12:45 – Ed: An HDBuzz article on the different mice used in Huntington’s disease research is coming soon

13:47 – Ed and Jeff are now reporting from the final science session – late breaking hot topics. Jeff is the first speaker in the session!

13:56 – Jeff studies metabolites in several tissues in HD mice. Tissues like brain, fat and liver are all changed differently by the mutation.

14:00 – Metabolic changes Jeff found in HD mouse blood mirror the changes in the brain – could be useful for studying human patients

14:19 – Dimebon showed no benefit for HD in big trial- HORIZON. The quest for treatments for thinking probs continues.

14:21 – However, HORIZON study recruited rapidly and was run efficiently – good news for future trials of upcoming treatments – Bernhard Landwehrmeyer

14:42 – Chemical ‘tattoos’ are added to DNA by enzymes. HD messes this up. HDAC inhibitor drugs should help – a trial’s underway – Larry Marsh

14:50 – There are many different DNA ‘tattoos’ = many ways to try to improve things with drugs. Animal studies will identify best ones – Marsh

15:10 – Jeff: Clare van Eyk uses fruit flies to try and understand how the mutated huntingtin gene kills brain cells

15:12 – ‘RNA’, as well as protein might contribute to brain cells dying – Clare

15:13 – Jennifer Thompson is studying the psychiatric symptoms of HD, like apathy and depression, which can be devastating

15:16 – Apathy is incredibly common in HD, and worsens over time – Thompson

15:18 – Interestingly, depression is also common in HD, but doesn’t seem to change much over time – Thompson

15:36 – Robi Blumenstein of CHDI – like a chess game, we need to think far ahead if we’re going to beat Huntington’s disease

15:40 – Success is a three-legged stool: (1) an effective treatment (2) the ability to test it and (3) enough trial volunteers – Blumenstein

16:00 – Lots of HD family members needed for trials, now & future. Find out how to get involved at Enroll-HD.org

Share on facebook
Share on twitter
Share on pinterest
Share on email

Latest Research Articles

Scientists identify precisely how pridopidine works in models of Huntington’s disease

Published date: 12 June, 2021

Pridopidine is a drug developed to treat Huntington’s disease (HD) and now scientists have a clearer understanding of how it works in the body and brain. In a series of academic papers, researchers figured out that pridopidine is working by targeting a particular receptor protein called S1R. With this new understanding, the researchers believe pridopidine ... Read more

Huntington's disease therapeutics conference 2021 – Day 3

Published date: 29 April, 2021

We are back for the last day of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can find with the hashtag #HDTC2021. The final session of the conference will provide the latest news on more Huntington’s disease clinical programs. A new way ... Read more

Huntington's disease therapeutics conference 2021 – Day 2

Published date: 28 April, 2021

We are back with Day 2 of the virtual 2021 CHDI Therapeutics conference. This article summarises our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning session focussed on promising HD therapeutics that are in preclinical development and the afternoon session covered different ... Read more

Huntington’s disease therapeutics conference 2021 – Day 1

Published date: 28 April, 2021

The CHDI Therapeutics Conference 2021 kicked off today. This article summarizes our live Twitter updates on the exciting science being presented, which you can continue to follow with the hashtag #HDTC2021. The morning of Day 1 focused on clinical trial updates, while the afternoon explored genetic modifiers of HD and how they might be harnessed ... Read more

Huntington’s disease clinical trial round up

Published date: 26 April, 2021

It seems like the HD community has been inundated with updates from different companies and clinical trials recently. The news is far from complete doom and gloom; although there have been some real disappointments from some of the frontrunner trials, there are also positive updates from many different companies and lots of reasons for us ... Read more

Good news from uniQure: gene therapy trial on track, and promising data in animals

Published date: 15 April, 2021

Two recent press releases from uniQure provide welcome good news: the first ever HD gene therapy, known as AMT-130, has been administered via brain surgery to a small set of participants in an early safety trial. At the same time, uniQure has published findings in HD animal models that increase confidence in the drug’s ability ... Read more